Furthermore, apart from KDM5, some other KDMs may also be aberrantly expressed in BC, such as LSD1 [20] and KDM4s [21], which suggests that developing dual-targeted agents against KDM5 and other KDMs is also a potential strategy for BC therapy. This evidence concerns the gene KDM1A and breast cancer.